

Characteristics of trial participants, adherence and loss to follow-up.

Treatment comparison and trial	Mean age (years)	Proportion of male participants (%)	Baseline SBP/DBP (mm Hg)	Proportion remaining on randomised treatment [#] or achieving blood pressure goal [†] (%)		Loss to follow-up (%) ^{**}
				first listed	second listed	
Trials comparing active treatment and placebo						
<i>Angiotensin converting enzyme inhibitor-based regimens vs placebo</i>						
HOPE	66	73	139/79	71, 73		<1.0
PART2	61	82	133/79	72, 75		<1.0
PROGRESS	64	70	147/86	77, 79		0.0
QUIET	58	82	123/74	72, 75		<1.0
SCAT	61	89	130/78	NA		0.0
Means	64	74	140/81	73, 75		-
<i>Calcium antagonist-based regimens vs placebo</i>						
IDNT	59	67	159/87	NA		<1.0
NICOLE	60	79	129/78	77, 86		NA
PREVENT	57	80	129/79	69, 78		<1.0
SYST-EUR	70	33	174/85	75, 68		2.8
Means	66	48	148/75	74, 69		-
Trials comparing more intensive and less intensive blood pressure lowering strategies						
AASK	55	61	151/96	70, 68		0.0
ABCD (H)	58	67	155/98	49, 89		0.0
ABCD (N)	59	55	136/84	67, 86		0.0
HOT	62	53	169/105	55, 80		2.6
UKPDS-HDS	56	55	160/94	56, 91		4.1
Means	61	54	167/103	56, 80		-
Trials comparing Angiotensin receptor blocker-based regimens and control regimens						
IDNT	59	68	159/87	NA		<1.0
RENAAL	60	63	153/82	54, 47		<1.0
SCOPE	76	35	166/90	51, 34		<1.0
LIFE	67	46	174/98	77, 73		<1.0
Means	70	46	169/93	65, 58		-
Trials comparing regimens based on different drug classes						
<i>Angiotensin converting enzyme inhibitor-based regimens vs diuretic- or beta-blocker-based regimens</i>						
AASK	55	61	151/96	71, 68		0.0
ALLHAT	67	53	146/84	61, 71		2.3
ANBP2	72	49	168/91	58, 56		0.0
CAPPP	53	53	161/99	67, 86		<1.0
STOP-2	76	33	194/98	64, 62		0.0
UKPDS-HDS	56	54	160/94	78, 65		4.1
Means	65	51	157/90	63, 72		-
<i>Calcium antagonist-based regimens vs diuretic- or beta-blocker-based regimens</i>						
AASK	55	61	151/96	67, 66		0.0
ALLHAT	67	53	146/84	72, 71		2.2
CONVINCE	66	44	150/87	61, 60		NA
ELSA	55	55	163/101	64, 66		NA
INSIGHT	65	46	173/99	60, 67		2.3
NICS-EH	70	33	172/94	94, 94		2.8
NORDIL	60	49	173/106	77, 93		<1.0
SHELL	72	39	178/87	80, 76		NA
STOP-2	76	33	194/98	64, 62		0.0
VHAS	54	49	169/102	78, 77		NA
Means	66	48	159/92	75, 75		-
<i>Angiotensin converting enzyme inhibitor-based regimens vs calcium antagonist-based regimens</i>						
AASK	54	61	151/96	71, 67		0.0
ABCD (H)*	58	67	155/98	51, 46		0.0
ABCD (N)	59	55	136/84	42, 44		0.0
ALLHAT	67	53	146/84	61, 72		2.3
JMIC-B	65	69	146/82	94, 94		NA
STOP-2	76	33	194/98	64, 62		0.0
Means	68	51	154/87	63, 71		-

DBP, diastolic blood pressure; NA, not available; SBP, systolic blood pressure

[#] Proportion remaining on randomised treatment reported for all placebo-controlled studies and for studies comparing different active treatments

[†] Proportion achieving blood pressure goal reported for studies comparing more and less intensive blood-pressure lowering strategies

* ABCD(H): the calcium antagonist-based regimen was terminated for the subgroup of patients with hypertension by recommendation of the Data Safety Monitoring Committee. Patients in that subgroup were given the option to continue the study on an ACE-inhibitor-based regimen.

^{**} Proportion of trial subjects with unknown vital status